Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 7,400 shares, a growth of 13.8% from the December 15th total of 6,500 shares. Based on an average daily trading volume, of 11,800 shares, the short-interest ratio is presently 0.6 days.

Tema Oncology ETF Trading Down 0.1 %

Shares of CANC opened at $24.46 on Friday. The business’s 50 day moving average is $25.87 and its 200 day moving average is $27.63. Tema Oncology ETF has a 12-month low of $23.97 and a 12-month high of $30.11. The company has a market capitalization of $52.83 million, a PE ratio of 26.86 and a beta of 1.11.

Tema Oncology ETF Dividend Announcement

The business also recently announced a dividend, which was paid on Thursday, December 12th. Stockholders of record on Wednesday, December 11th were issued a $0.7283 dividend. The ex-dividend date was Wednesday, December 11th.

Institutional Trading of Tema Oncology ETF

A hedge fund recently bought a new stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans purchased a new position in Tema Oncology ETF (NASDAQ:CANC) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned approximately 19.01% of Tema Oncology ETF at the end of the most recent quarter.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.